GlassScriptPhysician profile
Erica C Garza
NPI 1043522378
$9,383.74
in general payments reported to CMS, 2019-2025
25 companies · $7,041 in 2025
The $7,041 reported for 2025 was more than what 98% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $250 · 2021: $303 · 2022: $515 · 2023: $408 · 2024: $358 · 2025: $7,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,600 · Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,600.00 |
| Food and Beverage | $1,207.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $6,600.00 | 2025 | Ardeograft, Surgraft, Vitograft |
| Mayne Pharma Commercial LLC | $455.35 | 2022-2025 | |
| Evofem Biosciences, INC. | $268.38 | 2021-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $245.37 | 2019-2022 | |
| Hologic Sales and Service, LLC | $233.07 | 2020-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $229.20 | 2019-2021 | |
| Roche Diagnostics Corporation | $188.11 | 2019-2020 | |
| Astellas Pharma US INC | $177.25 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $160.05 | 2023-2025 | Slynd |
| Sumitomo Pharma America, INC. | $121.57 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $111.31 | 2025 | Zurzuvae |
| Organon LLC | $92.40 | 2022-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $88.34 | 2019-2021 | |
| Coopersurgical, INC. | $80.14 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $79.16 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $45.53 | 2019 | |
| Vertical Pharmaceuticals, LLC | $40.44 | 2019 | |
| Bluewind Medical | $30.80 | 2024 | Revi |
| Allergan, INC. | $27.78 | 2019 | |
| Myovant Sciences INC. | $23.98 | 2022 | |
| Millicent US INC | $22.54 | 2025 | Femlyv |
| Scynexis, INC. | $18.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.23 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.27 | 2019 | |
| Covidien LP | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.